Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and ongoing portfolio ...

Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, added: “The X4 POSEIDON is a cutting-edge XRM system with unmatched image quality in its category for ...

Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, added: "The X4 POSEIDON is a cutting-edge XRM system with unmatched image quality in its category for ...

Bruker exceeded both EPS and revenue forecasts for Q4 2024. The company reported a 14.6% year-over-year increase in quarterly revenue. Stock price decreased by 0.77% despite the earnings beat ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Bruker BioSpin is the pioneer in the development of CryoProbe technology for high-resolution NMR with over 1,300 CryoProbes installed at customer sites worldwide during the last 14 years.

2025 Non-GAAP EPS Guidance: $2.67 to $2.72, representing 11% to 13% growth. Bruker Corp (NASDAQ:BRKR) reported a strong Q4 2024 with a 14.6% year-over-year increase in revenues, reaching $979.6 ...

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...

In its fourth quarter 2024 investor letter, The London Company SMID Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing ...